Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Study for the Safety and Efficacy of CD19-CAR-DNT Cells (RJMty19) in the Treatment of Relapsed or Refractory Autoimmune Diseases

NCT06316076 is registered in ClinicalTrials.gov with RenJi Hospital as lead sponsor.

NCT NCT06316076
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06316076 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Study for the Safety and Efficacy of CD19-CAR-DNT Cells (RJMty19) in the Treatment of Relapsed or Refractory Autoimmune Diseases
Lead sponsor
RenJi Hospital
Phase
Phase 1
Overall status
Unknown status
Start date
October 30, 2023
Completion date
June 30, 2026
Enrollment
48 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anti-neutrophil cytoplasmic antibody-associated vasculitis, idiopathic inflammatory myopathies, systemic lupus erythematosus, systemic sclerosis